Business Context and Reporting Period
This Form 8-K filing by SINTX Technologies, Inc. (SINT) reports a complete turnover of the Board of Directors effective April 3, 2025. The filing was submitted on April 8, 2025, pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes Versus Prior Period
The primary material change is the resignation of five directors and the simultaneous appointment of five new directors.
- Resignations: B. Sonny Bal, David Truetzel, Jeffrey White, Eric Stookey, and Mark Froimson resigned effective April 3, 2025. The resignations were not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointments: Jay M. Moyes, Robert D. Mitchell, Mark Anderson, Chris Lyons, and Gregg Honigblum were appointed to the Board effective April 3, 2025.
Guidance, Outlook, and Management Commentary
The filing provides biographical details for the new directors, highlighting their extensive experience in finance, life sciences, and the medical device industry:
- Jay M. Moyes: Appointed Chair of the Audit Committee. Former CFO of Sera Prognostics, Myriad Genetics, and Amedica Corporation (now SINTX).
- Robert D. Mitchell: Appointed Chair of the Nominating and Governance Committee. Former President of Endologix and Executive Chairman of Life Seal Vascular.
- Mark Anderson: Appointed Chair of the Compensation Committee. Over 35 years of experience with Boston Scientific.
- Chris Lyons: Partner at BiotechExec and former CEO of Southern Metrics Consulting. Former executive at Medtronic and Smith & Nephew.
- Gregg Honigblum: Current Chief Strategy Officer of the Company. Former Managing Director at FNEX Capital and Westlake Securities.
Compensation for the new non-employee directors (Moyes, Mitchell, Anderson, Lyons) will be similar to previous non-employee directors as described in the 2025 Form 10-K. Mr. Honigblum, as an employee, will not receive additional compensation for board service.
Investor Verification Checklist
- Verify the specific compensation packages for the new non-employee directors in the most recent Form 10-K.
- Confirm the effective dates of the resignations and appointments to ensure no gap in board quorum.
- Review the Company's recent financial performance (Form 10-K or 10-Q) to understand the context of this governance shift, as no financial data is included in this 8-K.
- Monitor future filings for the election of directors at the next annual meeting, as the new appointees serve until their successors are elected.